We use cookies on our website. Carry on browsing if you’re happy with this or find out more

Site Leadership Team

:

Ben Porter-Brown, BSc MBBS FFPM

Ben Porter Brown card

VP, Clinical Development

Ben joined Kymab in 2018 as VP of Clinical Development and Project Team Leader for its lead immunology asset, the anti-OX40L mAb, Amlitelimab SAR445229 (formerly KY1005). Ben led the development of the successful Phase 2a Atopic Dermatitis study.

Prior to joining Kymab Ben spent 16 years at Roche-Genentech, he worked in clinical development in a variety of roles including Global Development Leader for the anti-IL-6 mAb, tocilizumab (Acterma). and Global Head of Infectious Diseases with a focus on influenza, Hepatitis B and antimicrobial resistance and sat on a variety of cross therapeutic development review and leadership committees. Ben trained in medicine at Imperial College, London where he also completed a degree in Neuropharmacology and Neuroendocrinology. Ben is a Fellow of the Faculty of Pharmaceutical Medicine at the Royal College of Physicians in the UK.